Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells

Cancer Biology and Therapy

Volumn 16, Issue 11, 2015, Pages 1585-1592

  Zhang, Lei ^a   Zhang, Fan ^a   Zhang, Wenjun ^a,b   Chen, Lu ^a   Gao, Neng ^a   Men, Yulong ^a   Xu, Xiaojun ^c   Jiang, Ying ^a  

^a TONGJI UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

combination; DNA double strand break repair; Harmine; homologous recombination repair; Rad51

Indexed keywords

HARMINE; HISTONE H2AX; RAD51 PROTEIN; ANTINEOPLASTIC AGENT; RAD51 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOTOXICITY; DNA END JOINING REPAIR; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; LIVER CELL CARCINOMA; M PHASE CELL CYCLE CHECKPOINT; PROTEIN EXPRESSION; RECOMBINATION REPAIR; WESTERN BLOTTING; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; DOUBLE STRANDED DNA BREAK; DRUG EFFECTS; DRUG SCREENING; LIVER NEOPLASMS; METABOLISM; S PHASE CELL CYCLE CHECKPOINT; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA BREAKS, DOUBLE-STRANDED; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE CELL CYCLE CHECKPOINTS; HARMINE; HUMANS; LIVER NEOPLASMS; RAD51 RECOMBINASE; RECOMBINATIONAL DNA REPAIR; S PHASE CELL CYCLE CHECKPOINTS;

EID: 84948575789     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1078021     Document Type: Article

References (40)

1. D.Hanahan, R.A.Weinberg. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
2. T.D.Halazonetis, V.G.Gorgoulis, J.Bartek. An oncogene-induced DNA damage model for cancer development. Science 2008; 319:1352-5; PMID:18323444; http://dx.doi.org/10.1126/science.1140735
3. G.Chu. Double strand break repair. J Biol Chem 1997; 272:24097-100; PMID:9305850; http://dx.doi.org/10.1074/jbc.272.39.24097
4. M.Shrivastav, L.P.De Haro, J.A.Nickoloff. Regulation of DNA double-strand break repair pathway choice. Cell Res 2008; 18:134-47; PMID:18157161; http://dx.doi.org/10.1038/cr.2007.111
5. T.Helleday, E.Petermann, C.Lundin, B.Hodgson, R.A.Sharma. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8:193-204; PMID:18256616; http://dx.doi.org/10.1038/nrc2342
6. Z.Mao, Y.Jiang, X.Liu, A.Seluanov, V.Gorbunova. DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells. Neoplasia 2009; 11:683-91; PMID:19568413; http://dx.doi.org/10.1593/neo.09312
7. E.Willmore, S.de Caux, N.J.Sunter, M.J.Tilby, G.H.Jackson, C.A.Austin, B.W.Durkacz. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 2004; 103:4659-65; PMID:15010369; http://dx.doi.org/10.1182/blood-2003-07-2527
8. Y.Zhao, H.D.Thomas, M.A.Batey, I.G.Cowell, C.J.Richardson, R.J.Griffin, A.H.Calvert, D.R.Newell, G.C.Smith, N.J.Curtin. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 2006; 66:5354-62; PMID:16707462; http://dx.doi.org/10.1158/0008-5472.CAN-05-4275
9. M.Srivastava, M.Nambiar, S.Sharma, S.S.Karki, G.Goldsmith, M.Hegde, S.Kumar, M.Pandey, R.K.Singh, P.Ray, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell 2012; 151:1474-87; PMID:23260137; http://dx.doi.org/10.1016/j.cell.2012.11.054
10. B.Budke, J.H.Kalin, M.Pawlowski, A.S.Zelivianskaia, M.Wu, A.P.Kozikowski, P.P.Connell. An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. J Med Chem 2013; 56:254-63; PMID:23231413; http://dx.doi.org/10.1021/jm301565b
11. B.Budke, H.L.Logan, J.H.Kalin, A.S.Zelivianskaia, W.Cameron McGuire, L.L.Miller, J.M.Stark, A.P.Kozikowski, D.K.Bishop, P.P.Connell. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res 2012; 40:7347-57
12. F.Huang, N.A.Motlekar, C.M.Burgwin, A.D.Napper, S.L.Diamond, A.V.Mazin. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol 2011; 6:628-35; PMID:21428443; http://dx.doi.org/10.1021/cb100428c
13. N.Hosoya, K.Miyagawa. Targeting DNA damage response in cancer therapy. Cancer Sci 2014; 105:370-88; PMID:24484288; http://dx.doi.org/10.1111/cas.12366
14. N.Gockler, G.Jofre, C.Papadopoulos, U.Soppa, F.J.Tejedor, W.Becker. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J 2009; 276:6324-37; PMID:19796173; http://dx.doi.org/10.1111/j.1742-4658.2009.07346.x
15. M.Bergstrom, G.Westerberg, B.Langstrom. 11C-harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies. Nucl Med Biol 1997; 24:287-93; PMID:9257326; http://dx.doi.org/10.1016/S0969-8051(97)00013-9
16. Y.Li, R.Sattler, E.J.Yang, A.Nunes, Y.Ayukawa, S.Akhtar, G.Ji, P.W.Zhang, J.D.Rothstein. Harmine, a natural β-carboline alkaloid, upregulates astroglial glutamate transporter expression. Neuropharmacol 2011; 60:1168-75; PMID:21034752; http://dx.doi.org/10.1016/j.neuropharm.2010.10.016
17. Y.Song, D.Kesuma, J.Wang, Y.Deng, J.Duan, J.H.Wang, R.Z.Qi. Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine. Biochem Biophys Res Commun 2004; 317:128-32; PMID:15047157; http://dx.doi.org/10.1016/j.bbrc.2004.03.019
18. Y.Ma, M.Wink. The β-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res 2010; 24:146-9; PMID:19548284; http://dx.doi.org/10.1002/ptr.2860
19. F.Zaker, A.Oody, A.Arjmand. A study on the antitumoral and differentiation effects of peganum harmala derivatives in combination with ATRA on leukaemic cells. Arch Pharm Res 2007; 30:844-9; PMID:17703736; http://dx.doi.org/10.1007/BF02978835
20. T.P.Hamsa, G.Kuttan. Harmine activates intrinsic and extrinsic pathways of apoptosis in B16F-10 melanoma. Chinese Med 2011; 6:11; PMID:21429205; http://dx.doi.org/10.1186/1749-8546-6-11
21. A.Seluanov, Z.Mao, V.Gorbunova. Analysis of DNA double-strand break (DSB) repair in mammalian cells. J Vis Exp 2010; 8(43). pii: 2002. doi: 10.3791/2002
22. A.Seluanov, D.Mittelman, O.M.Pereira-Smith, J.H.Wilson, V.Gorbunova. DNA end joining becomes less efficient and more error-prone during cellular senescence. Proc Natl Acad Sci USA 2004; 101:7624-9
23. Z.Mao, C.Hine, X.Tian, M.Van Meter, M.Au, A.Vaidya, A.Seluanov, V.Gorbunova. SIRT6 promotes DNA repair under stress by activating PARP1. Science 2011; 332:1443-6; PMID:21680843; http://dx.doi.org/10.1126/science.1202723
24. Z.Mao, A.Seluanov, Y.Jiang, V.Gorbunova. TRF2 is required for repair of nontelomeric DNA double-strand breaks by homologous recombination. Proc Natl Acad Sci USA 2007; 104:13068-73
25. Z.Mao, X.Tian, M.Van Meter, Z.Ke, V.Gorbunova, A.Seluanov. Sirtuin 6 (SIRT6) rescues the decline of homologous recombination repair during replicative senescence. Proc Natl Acad Sci USA 2012; 109:11800-5
26. S.Chen, C.Wang, L.Sun, D.L.Wang, L.Chen, Z.Huang, Q.Yang, J.Gao, X.B.Yang, J.F.Chang, et al. RAD6 promotes homologous recombination repair by activating the autophagy-mediated degradation of heterochromatin protein HP1. Mol Cell Biol 2015; 35:406-16; PMID:25384975; http://dx.doi.org/10.1128/MCB.01044-14
27. J.Essers, A.B.Houtsmuller, L.van Veelen, C.Paulusma, A.L.Nigg, A.Pastink, W.Vermeulen, J.H.Hoeijmakers, R.Kanaar. Nuclear dynamics of RAD52 group homologous recombination proteins in response to DNA damage. EMBO J 2002; 21:2030-7; PMID:11953322; http://dx.doi.org/10.1093/emboj/21.8.2030
28. A.A.Davies, J.Y.Masson, M.J.McIlwraith, A.Z.Stasiak, A.Stasiak, A.R.Venkitaraman, S.C.West. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 2001; 7:273-82; PMID:11239456; http://dx.doi.org/10.1016/S1097-2765(01)00175-7
29. Q.Liu, S.Guntuku, X.S.Cui, S.Matsuoka, D.Cortez, K.Tamai, G.Luo, S.Carattini-Rivera, F.DeMayo, A.Bradley, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000; 14:1448-59; PMID:10859164; http://dx.doi.org/10.1101/gad.840500
30. S.P.Jackson, J.Bartek. The DNA-damage response in human biology and disease. Nature 2009; 461:1071-8; PMID:19847258; http://dx.doi.org/10.1038/nature08467
31. B.B.Zhou, S.J.Elledge. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408:433-9; PMID:11100718; http://dx.doi.org/10.1038/35044005
32. P.C.Fong, D.S.Boss, T.A.Yap, A.Tutt, P.Wu, M.Mergui-Roelvink, P.Mortimer, H.Swaisland, A.Lau, M.J.O'Connor, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New Engl J Med 2009; 361:123-34; PMID:19553641; http://dx.doi.org/10.1056/NEJMoa0900212
33. M.W.Audeh, J.Carmichael, R.T.Penson, M.Friedlander, B.Powell, K.M.Bell-McGuinn, C.Scott, J.N.Weitzel, A.Oaknin, N.Loman, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376:245-51; PMID:20609468; http://dx.doi.org/10.1016/S0140-6736(10)60893-8
34. A.Tutt, M.Robson, J.E.Garber, S.M.Domchek, M.W.Audeh, J.N.Weitzel, M.Friedlander, B.Arun, N.Loman, R.K.Schmutzler, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376:235-44; PMID:20609467; http://dx.doi.org/10.1016/S0140-6736(10)60892-6
35. J.M.Boeira, A.F.Viana, J.N.Picada, J.A.Henriques. Genotoxic and recombinogenic activities of the two β-carboline alkaloids harman and harmine in Saccharomyces cerevisiae. Mutat Res 2002; 500:39-48; PMID:11890933; http://dx.doi.org/10.1016/S0027-5107(01)00294-9
36. J.M.Boeira, J.da Silva, B.Erdtmann, J.A.Henriques. Genotoxic effects of the alkaloids harman and harmine assessed by comet assay and chromosome aberration test in mammalian cells in vitro. Pharmacol Toxicol 2001; 89:287-94; PMID:11903953; http://dx.doi.org/10.1034/j.1600-0773.2001.d01-162.x
37. J.Ishida, H.K.Wang, K.F.Bastow, C.Q.Hu, K.H.Lee. Antitumor agents 201. Cytotoxicity of harmine and β-carboline analogs. Bioorg Med Chem Lett 1999; 9:3319-24; PMID:10612592; http://dx.doi.org/10.1016/S0960-894X(99)00598-3
38. X.Chen, L.J.Ko, L.Jayaraman, C.Prives. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996; 10:2438-51; PMID:8843196; http://dx.doi.org/10.1101/gad.10.19.2438
39. K.M.Ryan, K.H.Vousden. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 1998; 18:3692-8; PMID:9632751
40. F.Stahler, K.Roemer. Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53. Oncogene 1998; 17:3507-12; PMID:10030675; http://dx.doi.org/10.1038/sj.onc.1202245